Our data suggests an explanation for the anti-tumor activity of mTOR inhibition in a clinical trial of RCC[35], especially in those RCCs with PTEN alterations, and these data support further trials of mTOR inhibitors in RCC and other HIF-activated cancers. Here, MTOR is linked to neoplasm.